<DOC>
	<DOC>NCT02344303</DOC>
	<brief_summary>Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and supratherapeutic doses.</brief_summary>
	<brief_title>Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals</brief_title>
	<detailed_description>- Part A of the study will assess clinical safety data of TRV130 - Part B of the study will assess the effect of single dose TRV130 on QTc</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 45 inclusive. Women must be either a) postmenopausal; b) surgically sterile; c) of childbearing potential and practicing contraception or remaining sexually inactive. Men must be willing to abstain from sperm donation from the time of Screening through the Followup Visit and, if sexually active with a woman of childbearing potential, must be protected by acceptable forms of effective contraception through the Followup Visit. Past or present diseases including, but not limited to, significant medical abnormalities including: psychiatric, neurologic, pulmonary, cardiac, gastrointestinal, genitourinary, renal, metabolic, endocrinologic or autoimmune disorders. Has previously participated in another TRV130 clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>